N-acetylglucosamine for Synucleinopathy Constipation and Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for effectively managing symptoms of synucleinopathies, particularly constipation and alpha-synuclein aggregation, which are prevalent in Parkinson's Disease and other related disorders, and impact both gastrointestinal and central nervous system functions.
Innovation Solution
Administration of N-acetylglucosamine or its analogues/derivatives to treat constipation and solubilize alpha-synuclein aggregates, thereby normalizing motor function in both the gut and central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for synucleinopathies, then current standard care is provided, but effective management of constipation and alpha-synuclein aggregation is not achieved
Solution Approach 1:
The patent changes the chemical parameter by introducing N-acetylglucosamine, a glycosaminoglycan precursor, which modifies the biochemical environment to inhibit alpha-synuclein aggregation and improve gastrointestinal motilation. This chemical parameter change enables effective treatment of synucleinopathies where conventional treatments fail.
2Reliability
If N-acetylglucosamine is administered, then constipation symptoms are reduced and alpha-synuclein aggregates decrease, but the mechanism of action is not fully understood
Solution Approach 1:
The patent identifies N-acetylglucosamine as an intermediary substance that mediates between the administration and the therapeutic effects. It serves as a precursor for glycosaminoglycan synthesis, which then exerts the protective effects against alpha-synuclein aggregation and improves gastrointestinal function, though the complete signaling pathway remains partially elucidated.
3Adaptability or versatility
If treatments are developed for synucleinopathies, then motor and gastrointestinal functions can be improved, but current options are insufficient
Solution Approach 1:
The patent develops a universal treatment approach using N-acetylglucosamine that addresses multiple symptoms of synucleinopathies simultaneously, including constipation, alpha-synuclein aggregation, and gastrointestinal motilation. This multi-functional approach provides versatile treatment options that conventional single-target therapies cannot achieve.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
N-acetylglucosamine effectively reduces constipation symptoms and decreases alpha-synuclein aggregates, improving bowel movements and motor function, as demonstrated in pilot studies with Parkinson's Disease patients.
Implementation Method 1
post-translational modification of GIcNAc specifically O-GIcNAcylation at threonine residue 72 (Thr72) may have a role in regulating protein folding and inhibiting Parkinson's Disease-associated a-synuclein (aSyn) aggregation
Implementation Method 2
increasing the expression of sulphated glycosaminoglycan (GAG) which promotes proper gut functioning
Data Source
Figure 1
AI summary
Provided herein are methods of treating constipation in subjects in need thereof. The method includes administering a therapeutically effective dosage of N-acetylglucosamine. Subjects who may benefit from treatment include those having synucleinopathies, including Parkinson's Disease.